IP Library › Granted Patent US 12,427,112
Granted Patent B2
US 12,427,112 · App. 17/831,071 · Granted Sep 30, 2025

Method for preparing transmembrane pH-gradient vesicles

Inventors: Jean-Christophe Leroux (Zurich, CH); Vincent Forster (Zurich, CH); Valentina Agostoni (Montreal, CA)
Assignee: Versantis AG
A61K9/1277A61K9/127
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,112
App. No.
17/831,071
Granted
Sep 30, 2025
Kind
B2
Abstract

A method for preparing transmembrane pH-gradient vesicles is provided. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l, wherein the matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, wherein the suspension buffer differs from the basic or acidic buffer in pH value.

Claims (15)

1. A method for preparing transmembrane pH-gradient vesicles, comprising the steps of:

a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l, wherein the matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers,

b) mixing the vesicles with a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and

c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, wherein the suspension buffer differs from the basic or acidic buffer in pH value.

2. The method according to claim 1 , wherein the vesicles prepared in step a) are sterilized to obtain sterilized vesicles prior to carrying out step b) with these sterilized vesicles.

3. The method according to claim 1 , wherein the vesicles are stored for a first period of time prior to carrying out step b).

4. The method according to claim 1 , wherein step b) is carried out at a temperature that is below a phase transition temperature of the matrix substance.

5. The method according to claim 1 , wherein step b) is carried out at a temperature of not more than 35° C.

6. The method according to claim 1 , wherein the osmolarity of the basic or acidic buffer is at least 250 mOsm/l.

7. The method according to claim 1 , wherein the mixture of the aqueous medium and the basic or acidic buffer in which the buffer-filled vesicles are suspended at the end of step b) has an osmolarity of at least 200 mOsm/l.

8. The method according to claim 1 , wherein the neutralizing solution has an osmolarity of between 250 mOsm/l and 550 mOsm/l.

9. The method according to claim 1 , wherein the neutralizing solution comprises at least one substance chosen from the group consisting of glycerol, xylitol, TRIS, glucose, magnesium salts, sodium hydroxide, sodium salts and calcium salts.

10. The method according to claim 1 , wherein the pH value of the suspension buffer containing the transmembrane pH-gradient vesicles is in a range of 5.5 to 8.5.

11. The method according to claim 1 , wherein the aqueous medium is chosen from the group consisting of water, aqueous solutions of organic salts, aqueous solutions of inorganic salts, aqueous solutions of organic substances, and combinations thereof.

12. The method according to claim 1 , wherein the matrix substance is chosen from the group consisting of dipalmitoylphosphatidylcholine, 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[methoxy(PEG)-2000], cholesterol and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, and combinations thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2026
From: VERSANTIS AG
To: GENFIT
Reel/Frame 073455/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2022
From: LEROUX, JEAN-CHRISTOPHE; FORSTER, VINCENT; AGOSTONI, VALENTINA
To: ETH ZURICH
Reel/Frame 060107/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2022
From: ETH ZURICH
To: VERSANTIS AG
Reel/Frame 060107/0543 →
Priority Claims (1)
EP 15166247 · May 4, 2015 · regional
Continuity (2)
Continuation 15567878
Related Publication 20220287971A1 · Sep 15, 2022
References Cited (117)
US 4508703A · Redziniak et al. · 1985 [cited by applicant]
US 4532089A · MacDonald · 1985 [cited by applicant]
US 4792331A · Philippot et al. · 1988 [cited by applicant]
US 5049392A · Weiner et al. · 1991 [cited by applicant]
US 5077056A · Bally et al. · 1991 [cited by applicant]
US 5094854A · Ogawa et al. · 1992 [cited by applicant]
US 5185154A · Lasic et al. · 1993 [cited by applicant]
US 5230899A · Park et al. · 1993 [cited by applicant]
US 5393530A · Schneider · 1995 [cited by examiner]
US 5622713A · Mehlhorn · 1997 [cited by applicant]
US 5686309A · Frank et al. · 1997 [cited by applicant]
US 5766627A · Sankaram et al. · 1998 [cited by applicant]
US 5773024A · Unger et al. · 1998 [cited by applicant]
US 5807572A · Kim et al. · 1998 [cited by applicant]
US 5939096A · Clerc et al. · 1999 [cited by applicant]
US 6045824A · Kim et al. · 2000 [cited by applicant]
US 6106858A · Ye et al. · 2000 [cited by applicant]
US 6149937A · Camu et al. · 2000 [cited by applicant]
US 6162462A · Bolotin et al. · 2000 [cited by applicant]
US 6306432B1 · Shirley et al. · 2001 [cited by applicant]
US 6544549B1 · Boni et al. · 2003 [cited by applicant]
US 8022279B2 · Mayer et al. · 2011 [cited by applicant]
US 8951450B2 · Shimizu et al. · 2015 [cited by applicant]
US 9226984B2 · Petersen et al. · 2016 [cited by applicant]
US 9526761B2 · Hellerbrand et al. · 2016 [cited by applicant]
US 9820941B2 · Madsen et al. · 2017 [cited by applicant]
US 11376218B2 · Leroux · 2022 [cited by examiner]
US 20020136762A1 · See et al. · 2002 [cited by applicant]
US 20030224039A1 · Boni et al. · 2003 [cited by applicant]
US 20050031679A1 · Unger et al. · 2005 [cited by applicant]
US 20050118249A1 · Webb · 2005 [cited by examiner]
US 20060034907A1 · Nagaike et al. · 2006 [cited by applicant]
US 20060159736A1 · Zalipsky et al. · 2006 [cited by applicant]
US 20060239925A1 · Wada et al. · 2006 [cited by applicant]
US 20070269502A1 · Pliura et al. · 2007 [cited by applicant]
US 20080107724A1 · Szebeni et al. · 2008 [cited by applicant]
US 20080274172A1 · Moscoso Del Prado et al. · 2008 [cited by applicant]
US 20090017108A1 · Yuzhakov · 2009 [cited by applicant]
US 20090092662A1 · Huang et al. · 2009 [cited by applicant]
US 20090092663A1 · Ponzoni et al. · 2009 [cited by applicant]
US 20090269396A1 · Cipolla et al. · 2009 [cited by applicant]
US 20100021531A1 · Yoshino et al. · 2010 [cited by applicant]
US 20100305500A1 · Lambert et al. · 2010 [cited by applicant]
US 20110070292A1 · Javeri et al. · 2011 [cited by applicant]
US 20110105995A1 · Zhu et al. · 2011 [cited by applicant]
US 20130230457A1 · Reed et al. · 2013 [cited by applicant]
US 20130259922A1 · Haas et al. · 2013 [cited by applicant]
US 20130316980A1 · Tchirikov · 2013 [cited by applicant]
US 20140205543A1 · Penate-Medina et al. · 2014 [cited by applicant]
US 20150216802A1 · Leroux et al. · 2015 [cited by applicant]
US 20150309057A1 · Gavin et al. · 2015 [cited by applicant]
AU 008203032A1 · 2008 [cited by applicant]
CN 02626390B · 2013 [cited by applicant]
CN 03182333A · 2013 [cited by applicant]
CN 102716089B · 2013 [cited by applicant]
EP 0087993A1 · 1983 [cited by applicant]
EP 0331504A1 · 1989 [cited by applicant]
EP 0346472A1 · 1989 [cited by applicant]
EP 0461662A1 · 1991 [cited by applicant]
EP 0565361A1 · 1993 [cited by applicant]
EP 547580A1 · 2005 [cited by applicant]
EP 253308A1 · 2010 [cited by applicant]
EP 394640A1 · 2011 [cited by applicant]
EP 433619A1 · 2012 [cited by applicant]
EP 2474351A1 · 2012 [cited by applicant]
JP 564739A · 1993 [cited by applicant]
JP 69710A · 1994 [cited by applicant]
JP 2008136967A · 2008 [cited by applicant]
JP 2012158576A · 2012 [cited by applicant]
WO 8501440A1 · 1985 [cited by applicant]
WO 8801864A1 · 1988 [cited by applicant]
WO 8905636A1 · 1989 [cited by applicant]
WO 9003808A1 · 1990 [cited by applicant]
WO 9007920A1 · 1990 [cited by applicant]
WO 9014105A1 · 1990 [cited by applicant]
WO 9015595A1 · 1990 [cited by applicant]
WO 9608234A1 · 1996 [cited by applicant]
WO 9632930A1 · 1996 [cited by applicant]
WO 9734582A1 · 1997 [cited by applicant]
WO 9912522A1 · 1999 [cited by applicant]
WO 9912523A1 · 1999 [cited by applicant]
WO 9913865A1 · 1999 [cited by applicant]
WO 9916426A2 · 1999 [cited by applicant]
WO 0009089A1 · 2000 [cited by applicant]
WO 0105372A2 · 2001 [cited by applicant]
WO 0195914A1 · 2001 [cited by applicant]
WO 03039512A1 · 2003 [cited by applicant]
WO 03075890A1 · 2003 [cited by applicant]
WO 2005048986A1 · 2005 [cited by applicant]
WO 2005102359A1 · 2005 [cited by applicant]
WO 2008040556A1 · 2008 [cited by applicant]
WO 2009009115A2 · 2009 [cited by applicant]
WO 2009091531A2 · 2009 [cited by applicant]
WO 2011038073A1 · 2011 [cited by applicant]
WO 2012079582A1 · 2012 [cited by applicant]
WO 2012117587A1 · 2012 [cited by applicant]
WO 2014013043A1 · 2014 [cited by applicant]
WO 2014023421A1 · 2014 [cited by applicant]
Bertrand et al.; “Supplementary information”; ACS Nano; 2010; pp. 1-16. [cited by applicant]
Bertrand et al.; “Transmembrane pH-Gradient Liposomes To Treat Cardiovascular Drug Intoxication”; ACS Nano; 2010; pp. 7552-7558; vol. 4:12. [cited by applicant]
Forster et al.; “Liposome-supported peritoneal dialysis for detoxification of drugs and endogenous metabolites”; Sci. Transl. Med.; 2014; pp. 1-9; vol. 6:258. [cited by applicant]
Forster et al.; “Treatment of calcium channel blocker-induced cardiovascular toxicity with drug scavenging liposomes”; Biomaterials; 2012; pp. 3578-3585; vol. 33. [cited by applicant]
Grit et al.; “Chemical stability of liposomes: implications for their physical stability”; Chemistry and Physics of Lipids; 1993; pp. 3-18; vol. 64. [cited by applicant]
Mayer et al.; “Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential”; Biochimica et Biophysica Acta; 1985; pp. 294-302; vol. 816. [cited by applicant]
Mayer et al.; “Uptake of Dibucaine into Large Unilamellar Vesicles in Response to a Membrane Potential”; The Journal of Biological Chemistry; 1985; pp. 802-808; vol. 260:2. [cited by applicant]
Nichols et al.; “Catecholamine Uptake and Concentration By Liposomes Maintaining pH Gradients”; Biochimica et Biophysica Acta; 1976; pp. 269-271; vol. 455. [cited by applicant]
Stevens et al.; “Formulation Kit for Liposomal Doxorubicin Composed of Lyophilized Liposomes”; Anticancer Research; 2003; pp. 439-442; vol. 23. [cited by applicant]
Woh et al.; “Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing”; Asian Journal of Pharmaceutical Sciences; 2013; pp. 88-95; vol. 8. [cited by applicant]
Zuidam et al..; “Sterilization of Liposomes by Heat Treatment”; Pharmaceutical Research; 1993; pp. 1591-1596; vol. 10:11. [cited by applicant]
Yunbo, “Functional Food Processing Technology”, China Quality and Standards Publishing & Media Co., Ltd., 2013, 23 pages (Relevant for reasons stated in CN Office Action 201680025547.4 translation, p. 3). [cited by applicant]
Antimisiaris et al., “Liposomes and Drug Delivery,” Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing, 2010 1-91. [cited by applicant]
Chang et al. “Clinical-development-of-liposome-based-drugs,” International Journal of Nanomedicine 2012:7 49-60. [cited by applicant]
Grit et al. “Chemical stability of liposomes: implications for their physical stability,” Chemistry and Physics of Lipids, 64 (1993) 3-18. [cited by applicant]
Examination Report dated May 28, 2020, in Australian Patent Application No. 2016256979. [cited by applicant]
Examination Report dated Nov. 30, 2020, in Australian Patent Application No. 2016256979. [cited by applicant]
Office Action dated Jul. 16, 2020, in Mexican Patent Application No. MX/a/2017/014130. [cited by applicant]
Office Action dated Sep. 1, 2020 in Brazilian Patent Application No. 1120170235781. [cited by applicant]